Breakthrough-Therapy Designation - An FDA Perspective

被引：12
|
作者：
Corrigan-Curay, Jacqueline [1 ]
Mckee, Amy E. [1 ]
Stein, Peter [1 ]
机构：
[1] US FDA, Silver Spring, MD 20993 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2018年 / 378卷 / 15期
关键词：
D O I：
10.1056/NEJMc1801222
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1457 / 1458
页数：2
相关论文
共 50 条
  • [31] Stock price effects of breakthrough therapy designation
    Hoffmann, David
    Van Dalsem, Shane
    David, Frank S.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2019, 18 (03) : 165 - 165
  • [32] Developing Standards for Breakthrough Therapy Designation in Oncology
    Horning, Sandra J.
    Haber, Daniel A.
    Selig, Wendy K. D.
    Ivy, S. Percy
    Roberts, Samantha A.
    Allen, Jeff D.
    Sigal, Ellen V.
    Sawyers, Charles L.
    [J]. CLINICAL CANCER RESEARCH, 2013, 19 (16) : 4297 - 4304
  • [33] Stock price effects of breakthrough therapy designation
    David Hoffmann
    Shane Van Dalsem
    Frank S. David
    [J]. Nature Reviews Drug Discovery, 2019, 18 : 165 - 165
  • [34] Characteristics of breakthrough therapy designation requests (BTDRs) submitted to the Office of Hematology and Oncology Products (OHOP), FDA.
    Suzman, Daniel L.
    Kluetz, Paul Gustav
    Mckee, Amy E.
    Ward, Ashley Flynn
    Marcus, Leigh Jessica
    Casak, Sandra J.
    Pazdur, Richard
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [35] DOES FDA BREAKTHROUGH DESIGNATION AFFECT HTA RECOMMENDATIONS IN TERMS OF TIMING AND OUTCOME?
    Cai, J.
    Wang, T.
    McAuslane, N.
    Liberti, L.
    [J]. VALUE IN HEALTH, 2019, 22 : S809 - S809
  • [36] Breakthrough Therapy Designation: Bringing Innovation Swiftly to Patients
    Arpita Shah
    [J]. Therapeutic Innovation & Regulatory Science, 2015, 49 : 256 - 261
  • [37] Breakthrough therapy designation for pancreatic cancer vaccine combo
    不详
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (10) : 2779 - 2780
  • [38] PARP inhibitor receives FDA breakthrough therapy designation in castration resistant prostate cancer: beyond germline BRCA mutations
    Helleday, T.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 (05) : 755 - 757
  • [39] Breakthrough Therapy Designation: Bringing Innovation Swiftly to Patients
    Shah, Arpita
    [J]. THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2015, 49 (02) : 256 - 261
  • [40] Impact of breakthrough therapy designation on cancer drug development
    Michael Shea
    Linda Ostermann
    Ryan Hohman
    Samantha Roberts
    Marina Kozak
    Ryan Dull
    Jeff Allen
    Ellen Sigal
    [J]. Nature Reviews Drug Discovery, 2016, 15 : 152 - 152
12345